Stockreport

Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder

Nasus Pharma Ltd. Ordinary Shares  (NSRX) 
PDF Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to EpiPen® 91% of study participants achieved t [Read more]